Literature DB >> 26424649

Primary Immunodeficiencies Associated with EBV Disease.

Jeffrey I Cohen1.   

Abstract

Epstein-Barr virus (EBV) infects nearly all humans and usually is asymptomatic, or in the case of adolescents and young adults, it can result in infectious mononucleosis. EBV-infected B cells are controlled primarily by NK cells, iNKT cells, CD4 T cells, and CD8 T cells. While mutations in proteins important for B cell function can affect EBV infection of these cells, these mutations do not result in severe EBV infection. Some genetic disorders affecting T and NK cell function result in failure to control EBV infection, but do not result in increased susceptibility to other virus infections. These include mutations in SH2D1A, BIRC4, ITK, CD27, MAGT1, CORO1A, and LRBA. Since EBV is the only virus that induces proliferation of B cells, the study of these diseases has helped to identify proteins critical for interactions of T and/or NK cells with B cells. Mutations in three genes associated with hemophagocytic lymphohistocytosis, PRF1, STXBP2, and UNC13D, can also predispose to severe chronic active EBV disease. Severe EBV infection can be associated with immunodeficiencies that also predispose to other viral infections and in some cases other bacterial and fungal infections. These include diseases due to mutations in PIK3CDPIK3R1, CTPS1, STK4, GATA2, MCM4, FCGR3A, CARD11, ATM, and WAS. In addition, patients with severe combined immunodeficiency, which can be due to mutations in a number of different genes, are at high risk for various infections as well as EBV B cell lymphomas. Identification of proteins important for control of EBV may help to identify new targets for immunosuppressive therapies.

Entities:  

Mesh:

Year:  2015        PMID: 26424649      PMCID: PMC6349415          DOI: 10.1007/978-3-319-22822-8_10

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  61 in total

1.  Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.

Authors:  Wei Bu; Gregory M Hayes; Hui Liu; Lorraine Gemmell; David O Schmeling; Pierce Radecki; Fiona Aguilar; Peter D Burbelo; Jennifer Woo; Henry H Balfour; Jeffrey I Cohen
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers.

Authors:  Jeffrey I Cohen; Lesia Dropulic; Amy P Hsu; Christa S Zerbe; Tammy Krogmann; Kennichi Dowdell; Ronald L Hornung; Jana Lovell; Nancy Hardy; Dennis Hickstein; Edward W Cowen; Katherine R Calvo; Stefania Pittaluga; Steven M Holland
Journal:  Clin Infect Dis       Date:  2016-05-11       Impact factor: 9.079

3.  Periodic Illness Associated With Epstein-Barr Virus: A New Diagnosis After a 22-Year Follow-up.

Authors:  Lesia K Dropulic; Mir A Ali; Amanda K Ombrello; Jeffrey I Cohen
Journal:  Clin Infect Dis       Date:  2016-03-29       Impact factor: 9.079

4.  An immunocompetent patient with a recurrence-free Epstein-Barr virus positive plasmacytoma possesses robust Epstein-Barr virus specific T-cell responses.

Authors:  Bithi Chatterjee; Laura Sahli; Obinna Chijioke; Philip Went; Christian Münz; Andreas Trojan
Journal:  Haematologica       Date:  2017-07-13       Impact factor: 9.941

5.  Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.

Authors:  Amy S Duffield; Maria Libera Ascierto; Robert A Anders; Janis M Taube; Alan K Meeker; Shuming Chen; Tracee L McMiller; Neil A Phillips; Haiying Xu; Aleksandra Ogurtsova; Alan E Berger; Drew M Pardoll; Suzanne L Topalian; Richard F Ambinder
Journal:  Blood Adv       Date:  2017-07-21

6.  Patients With Natural Killer (NK) Cell Chronic Active Epstein-Barr Virus Have Immature NK Cells and Hyperactivation of PI3K/Akt/mTOR and STAT1 Pathways.

Authors:  Matthew K Howe; Kennichi Dowdell; Hye Sun Kuehn; Qingxue Li; Geoffrey T Hart; Doreen Garabedian; Kelly Liepshutz; Amy P Hsu; Hua Su; Julie E Niemela; Jennifer L Stoddard; Gulbu Uzel; Evan Shereck; Laura Schulz; Tatyana Feldman; Sergio D Rosenzweig; Eric O Long; Lesia Dropulic; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2020-09-01       Impact factor: 5.226

7.  Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas.

Authors:  Julia Rühl; Carmen Citterio; Christine Engelmann; Tracey Haigh; Andrzej Dzionek; Johannes Dreyer; Rajiv Khanna; Graham S Taylor; Joanna B Wilson; Carol S Leung; Christian Münz
Journal:  J Clin Invest       Date:  2019-04-15       Impact factor: 14.808

Review 8.  The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.

Authors:  Olivia M Martinez; Sheri M Krams
Journal:  Transplantation       Date:  2017-09       Impact factor: 4.939

9.  Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease.

Authors:  Takeharu Minamitani; Yijie Ma; Hufeng Zhou; Hiroshi Kida; Chao-Yuan Tsai; Masanori Obana; Daisuke Okuzaki; Yasushi Fujio; Atsushi Kumanogoh; Bo Zhao; Hitoshi Kikutani; Elliott Kieff; Benjamin E Gewurz; Teruhito Yasui
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-28       Impact factor: 11.205

10.  Plasmacytoid dendritic cells respond to Epstein-Barr virus infection with a distinct type I interferon subtype profile.

Authors:  Cornelia Gujer; Anita Murer; Anne Müller; Danusia Vanoaica; Kathrin Sutter; Emilie Jacque; Nathalie Fournier; Jens Kalchschmidt; Andrea Zbinden; Riccarda Capaul; Andrzej Dzionek; Philippe Mondon; Ulf Dittmer; Christian Münz
Journal:  Blood Adv       Date:  2019-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.